Background
Despite the ongoing developments made in modern medical research, cancer remains the second most common cause of death in the United States [1] . Many modern treatments, such as radiation therapy and chemotherapy, have numerous adverse side-effects that may not become evident until months or years after treatment has ended [2 & 3] . Additionally, there exist few effective treatments for individuals diagnosed with late-stage cancers. There is a great need for continued research and development of novel treatment options to facilitate better clinical outcomes of cancer patients.
Our research of the drug AS1411 aims to address this need for improved cancer therapeutics. AS1411 is a guanine-rich oligonucleotide optimized for its anti-proliferative activity of cancer cells. Guanine-rich oligonucleotides (GROs) are short chains of [7] . ability to resist degradation by nucleases [5] . While the exact quadruplex structure of AS1411is unknown, at least 8 different forms have been detected using a size exclusion chromatography [6] . Additionally, AS1411 has specificity for cancer cells because it is capable of binding to nucleolin, a protein that is highly expressed on the surface on many types of cancer cells [8] .
AS1411 has shown promise in both in vitro and in vivo experiments. The GI50 values (the concentration required for 50% growth inhibition) for AS1411 were remarkably low for almost every tested cancer cell line despite the fact of having little effect in normal cell lines at similar concentrations [5] . Notably, the compound also inhibited tumor growth in mouse models despite displaying no toxicity in normal tissues.
These results imply that the anti-proliferative effects of AS1411 selectively target cancerous cells, unlike standard therapies. In 2003, AS1411 entered into a Phase 1 clinical trial in patients with advanced cancers. During this trial, there were no reports of severe side-effects and varying degrees of clinical activity. Most patients experienced disease stabilization, but one patient experienced a complete response; within 11 months [5] . Similar results were later replicated during phase 2 clinical trials, however the funding company, Antisoma, had to terminate ongoing trials due to the expensive failure of another drug compound in its pipeline [8] . AS1411 was tested in over 100 patients but only demonstrated strong activity in 7. However, these 7 patients exhibited strong results including substantial shrinkage and the complete disappearance of tumors [9] . It was discerned that in order to apply and optimize AS1411, a better understanding of the mechanism of action was required [8 & 9] . AS1411 is incorporated into the cell by macropinocytosis and that levels of macropinocytosis and anti-proliferative activity are correlated [10] . In particular, AS1411
induces cell death through a novel pathway known as methuosis, in which the cells ingest numerous vesicles causing eventual cell lysis [10 & 11] . Methuosis is a novel nonapoptotic cell death pathway that is characterized by displacement of the cytoplasm by large fluid-filled vacuoles derived from macropinosomes that ultimately induce cell lysis. Notably, this pathway involves the hyperstimulation of a number of oncogenic pathways that ultimately result in cell death [12] . The involvement of these oncogenic pathways makes methuosis highly promising as a possible target for the treatment of aggressive or late-stage disease. Although numerous compounds and proteins have been implicated in the pathway, many aspects of the pathway remain unknown.
The accumulation of guanine ribonucleotides can lead to the arrest of the cell cycle and an inhibition of cellular growth in human cells [13] . Further studies have Figure 2 . Reaction diagram representing the enzymatic activity of HGPRT. The enzyme serves as a transferase that converts guanine to guanosine monophosphate through the transference of a phosphoribosyl group from phosphoribosyl pyrophosphate to guanine. This creates guanosine monophosphate and pyrophosphate as end products.
suggested that the degradation of GROs (including AS1411) to the monomers of guanine-based purine compounds (GBPCs) such as guanine, guanosine, and guanosine monophosphate dictate the anti-proliferative effects in vitro [14] . Additionally, these anti-proliferative effects are dependent on hypoxanthine-guanine phosphoribosyltransferase (HGPRT), an enzyme in the purine salvage pathway ( Figure   2 ) [15] . HGPRT is a vital element of the purine salvage pathway and subsequently an important enzyme for creating the bases that will be sequestered into new DNA [16] . A loss of HGPRT function in cells makes them unable to recycle certain purines, and this causes deleterious effects. guanine plays a role in AS1411 activity [unpublished] ; however, more research is needed to elucidate the mechanism. This project will be combined with our previous unpublished research with the goal of definitively testing the stated hypothesis.
Ultimately, this knowledge will serve to guide further studies for optimizing AS1411 as a potential cancer treatment.
Specific Aims
The specific aim for this project was to investigate the possible role of HGPRT in the anti-proliferative activity of AS1411. If degradation to GBPCs is vital for AS1411 activity, then the loss of HGPRT function should result in a decrease of the compounds exhibited anti-proliferative effects.
Materials and Methods

Materials
Oligodeoxynucleotides, AS1411 (5′-GGTGGTGGTGGTTGTGGTGGTGGTGG), and negative control oligonucleotide, CRO (5′-CCTCCTCCTCCTTCTCCTCCTCCTCC) were purchased in the desalted form from Integrated DNA Technologies (Coralville, IA). 
Cell Lysis and Protein Collection
Flasks containing cells were placed on ice and media was removed. 
Protein Analysis by Western Blot
Samples for SDS-PAGE were prepared using 25 μg of protein, 4× loading buffer containing 10% β-mercaptoethanol, and distilled water to ensure samples of equal volumes. Samples were resolved using Novex 4 -20% tris-gylcine gels (Life Technologies) and then transferred onto polyvinylidine fluoride membranes (Fisher Scientific) in Tris-glycine transfer buffer (Life Technologies) containing 20% methanol.
Membranes were either blocked with 5% milk in tris-buffered saline containing 0.05% tween-20 (TBS-T) in TBS-T. The following primary concentrations were used for protein detection: HGPRT 1:500, and α-tubulin 1:1000. Secondary antibodies were used at a 1:10,000 concentration. Membranes probed with HGPRT primaries were detected using SuperSignal® West Dura ECL (Fisher Scientific) while α-tubulin was detected using Pierce® ECL Western Blotting Substrate (Fisher Scientific). Chemiluminescence was visualized using Amersham Hyperfilm™ (GE Healthcare, Little Chalfont, United Kingdom).
Cell Proliferation Assay
A549 cells were plated at a density of 1000 cells per well in 96 well plates (TPP) and incubated overnight to allow for adherence. Cells were treated in triplicate wells with either oligonucleotide, GBPC, or siRNAs. After treatments of varying duration, MTT (Sigma) was added in the dark at 1/10th total sample volume, and cells were incubated for 4 hours. Lysis buffer (10% SDS in 0.01 N HCl) was added at half of the original sample volume and incubated overnight to ensure complete cell lysis and dissolution of crystals. Plates were read at 570 nm, and relative absorbance values were exported to Microsoft Excel ® for further analysis [18 & 19] . GraphPad Prism was used to determine the level of statistical significance by ANOVA and/or t-test. 
Development of Thioguanine-Resistant A549 Cells
A549 cells were grown to ~70% confluency and then transferred to new flasks containing a 1.5 µM 6-thioguanine (Sigma). After cells grew to confluency, they were passaged into new flasks with 3 µM increases in concentration of 6-thioguanine. This was repeated until final concentrations of 6 µM and 15 µM of 6-thioguanine were established.
Results
Determining Optimal Conditions for AS1411 Anti-Proliferative Effects
In an effort to 
Determining Optimal Conditions for GBPC Anti-Proliferative Effects in A549 and
MDA-MB-231 Cells
As mentioned previously, guanine-based purine compounds (GBPCs), such as guanosine, have been shown to exhibit anti-proliferative effects in vitro [14] .
Furthermore, their toxicity appears to be dependent on HGPRT function [15] . To determine if AS1411 activity is similar to that seen in cells treated with GBPCs, A549
and MDA-MB-231 cells were treated 25 to 400 µM guanosine (Guo) ranging from 25 to 400 µM for 72 hours before cell proliferation assays were performed. A549 cells 
E f f e c t o f G u a n o s in e o n M B A -M D -2 3 1 C e ll P r o lif e r a t io n
C o n c e n tra tio n o f G u a n o s in e (  M ) After the GI50 of AS1411 in A549 cells and reliable HGPRT knockdown were established, A549 cells were transfected and then treated with AS1411 to test if HGPRT activity was necessary for AS1411 anti-proliferative effects. CRO (cytosine rich oligonucleotide) treatments in equal concentrations to AS1411 counterparts were used to determine if oligonucleotide treatment decreased relative proliferation as seen in previous studies with AS1411 [24] . Additionally, water was used as a vehicle control. In line with previous findings, AS1411 displayed strong anti-proliferative effects compared to vehicle and CRO control treatments. Transfected vehicle control treatments did not exhibit decreased proliferation, suggesting that transfection was not toxic to cells. Although consistent, this transfection data does not fully answer our previous question regarding siRNA knockdown of HGPRT. Was there no effect with AS1411 treatment because the compound works by a non-HGPRT dependent mechanism, or because a residual population of HGPRT exists to preserve anti-proliferative activity?
To answer this, we decided to test our siRNA HGPRT knockdown against GBPC antiproliferative activity. As mentioned previously, GBPCs have antagonistic effects on cellular growth, and these effects are known to be dependent on HGPRT activity [14 & 15] . If AS1411 and GBPC activity works by an analogous mechanism due to similar Expression knockdown via transfected siRNAs operates by engineering siRNAs with complimentary sequences to the mRNA of interest and delivering them into the cell via cationic liposomes [25] . Once inside the cell, the siRNAs integrate into the multiprotein RNAi induced silencing complex (RISC), which can target and degrade the desired mRNAs [26] . Although this process will knockdown the expression of a particular protein by a considerable amount, it will not target the preexisting proteins within the cell. For proteins with short half-lives, this is not problematic for the experimental procedure; however, some proteins can have half-lives of over 100 hours [27] . Additionally, the proteins of cells in stressed environments where cellular division has been slowed or stopped can actually increase their half-lives [28] . HGPRT has a half-life of over 48 hours [29] , which may be extended during periods of stress caused by treatments of AS1411 or Guo. Previous results demonstrate an incomplete ability to prevent HGPRT activity, which may be due in part to residual HGPRT inside the cell that is not silenced by siRNA transfection.
In order to test the activity of these compounds in a HGPRT deficient environment, A549 cells were incubated in TG in order to select for HGPRT mutant cells. As mentioned previously, TG is toxic to cells with functioning HGPRT. HGPRT can transfer a phosphoribosyl group onto TG, allowing it to be incorporated into the DNA and cause strand breakages [20 & 21] . The employed protocol was based on previous work [22] Additionally, the experiment lacked a CRO control to ensure that differences in proliferation can be attributed to AS1411 and Guo anti-proliferative effects and not simply to physiological differences in the two cell lines due to TG related stress.
Replication of the experiment with these additional controls would be necessary to confirm previous results.
Future Directions
Although these results suggest a similar mechanism for AS1411 and GBPCs, more work is necessary to confirm this hypothesis. Replication of these experiments in additional cell lines that are more responsive to Guo treatment would help to strengthen this results. Additionally, genomic testing of TG-incubated A549 cells would be crucial to confirm mutations in the HPRT1 gene compromised the function of HGPRT. Moreover, a CRISPR/Cas9 system could be used to create an HGPRT deficient cell line analogous to HGPRT mutants to further confirm that previous results were due to the loss of HGPRT function.
